Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer
Details : 68-Ga R11228 is a Radiolabelled Compounds drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
August 13, 2025
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
December 20, 2024
Radionetics Raises $52.5M Series A to Advance Radiopharmaceutical Pipeline and CEO
Details : Radionetics plans to use the proceeds to advance its pipeline of potent, small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) for a broad range of cancers.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 01, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $1,000.0 million
Deal Type : Acquisition
Radionetics Oncology Enters Into Strategic Agreement With Lilly
Details : Through the acquisition, Eli Lilly will leverage small molecule radioligand therapeutics targeting GPCRs using the Radionetics proprietary discovery platform for treating neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $140.0 million
January 07, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $1,000.0 million
Deal Type : Acquisition
GordonMD® Announces Investment in Radiopharmaceutical Biotech Radionetics Oncology
Details : The financing will focus on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications by using company's platform technology which uses small molecule targeting to deliver radioisotopes to a broad ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 17, 2023
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
August 21, 2023